Drug Profile
Phenyl butyrate - Akthelia Pharmaceuticals
Alternative Names: 4-Phenyl butyrate - Akthelia Pharmaceuticals; AKT-10081Latest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Akthelia Pharmaceuticals
- Class Antidiarrhoeals; Butyrates; Peptide antibiotics; Peptides
- Mechanism of Action Peptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Clostridium infections; Diarrhoea
Most Recent Events
- 17 Jan 2018 Phase-II development in Clostridium infections is ongoing in Iceland (Akthelia Pharmaceuticals pipeline, January 2018)
- 17 Jan 2018 Phase-II development in Diarrhoea is ongoing in Iceland (Akthelia Pharmaceuticals pipeline, January 2018)
- 18 Dec 2015 AKT 10081 is available for licensing as of 18 Dec 2015. http://www.akthelia.is/